US Pharma MarketingRoche bets $1B+ on DualityBio
Genentech taps DualityBio Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
DualityBio said Friday it will receive $45 million upfront from Roche’s Genentech to develop drugs that could be part of a new wave of antibody-drug conjugates.
The deal is centered on ...
Source: Endpoints News